Isotretinoin in the management of acne vulgaris: practical prescribing.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
revised:
20
04
2020
received:
13
01
2020
accepted:
13
07
2020
pubmed:
30
8
2020
medline:
22
6
2021
entrez:
30
8
2020
Statut:
ppublish
Résumé
Since it was first approved for use in 1982, isotretinoin has revolutionized the management of acne vulgaris. Despite almost four decades of widespread use, uncertainty still exists regarding the manner in which it is best prescribed. In this review, we provide an update on the pharmacokinetics, mechanism of action, contraindications, interactions, and appropriate dosing schedule of isotretinoin in the treatment of acne. We also discuss the safety of performing concurrent dermatological procedures in patients taking isotretinoin.
Substances chimiques
Dermatologic Agents
0
Isotretinoin
EH28UP18IF
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
451-460Informations de copyright
© 2020 the International Society of Dermatology.
Références
Vallerand IA, Lewinson RT, Farris MS, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018; 178(1): 76-85.
Chernyshov PV, Tomas-Aragones L, Manolache L, et al. Which acne treatment has the best influence on health-related quality of life? Literature review by the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. J Eur Acad Dermatol Venereol. 2018; 32(9): 1410-1419.
Costa CS, Bagatin E, Martimbianco A, et al. Oral isotretinoin for acne. Cochrane Database Syst Reveiws. 2018;(11):CD009435.
Tang GW, Russell RM. 13-Cis-retinoic acid is an endogenous compound in human serum. J Lipid Res. 1990; 31(2): 175-182.
Blaner WS. Cellular metabolism and actions of 13-cis-retinoic acid. J Am Acad Dermatol. 2001; 45(5): 129-135.
Gollnick H, Ehlert R, Rinck G, Orfanos CE. Retinoids: an overview of pharmacokinetics and therapeutic value. Methods Enzymol. 1990; 190: 291-304.
Colburn W, Gibson D, Wiens R, Hanigan J. Food increases the bioavailability of isotretinoin. J Clin Pharmacol. 1983; 23(11-12): 534-539.
Webster GF, Leyden JJ, Gross JA. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. J Am Acad Dermatol. 2013; 69(5): 762-767.
Allen JG, Bloxham DP. The pharmacology and pharmacokinetics of the retinoids. Pharmacol Ther. 1989; 40(1): 1-27.
Wiegand UW, Chou RC. Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol. 1998; 39(2): 8-12.
Thielitz A, Krautheim A, Gollnick H. Update in retinoid therapy of acne. Dermatol Ther. 2006; 19(5): 272-279. https://doi.org/10.1111/j.1529-8019.2006.00084.x.
Tsukada M, Schroder M, Roos TC, et al. 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol. 2000; 115(2): 321-327.
Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol. 2006; 126(10): 2178-2189.
Nelson AM, Cong Z, Gilliland KL, Thiboutot DM. TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells. Br J Dermatol. 2011; 165(3): 526-533.
Nelson AM, Zhao W, Gilliland KL, et al. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. J Clin Invest. 2008; 118(4): 1468-1478.
Melnik BC. Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Derm Venereol. 2017; 97(2): 173-181. https://doi.org/10.2340/00015555-2535.
Shi G, Liao P-Y, Cai X-L, et al. FoxO1 enhances differentiation and apoptosis in human primary keratinocytes. Exp Dermatol. 2018; 27(11): 1254-1260.
Rademaker M. Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris. Int J Dermatol. 2016; 55(5): 518-523.
King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol. 1982; 107(5): 583-590.
Norris DA, Osborn R, Robinson W, Tonnesen MG. Isotretinoin produces significant inhibition of monocyte and neutrophil chemotaxis in vivo in patients with cystic acne. J Invest Dermatol. 1987; 89(1): 38-43.
Papakonstantinou E, Aletras AJ, Glass E, et al. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol. 2005; 125(4): 673-684.
Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016; 74(5): 945-973.e33.
Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in acne. J Am Acad Dermatol. 2018; 78: S1-23.
Australian product information - Oratane (isotretinoin) soft capsules. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2016-PI-02513-1&d=202008091016933. [Accessed 20/04/2020]
Awazuhara H, Kawai H, Baba M, Matsui T, Komiyama A. Antigenicity of the proteins in soy lecithin and soy oil in soybean allergy. Clin Exp Allergy. 1998; 28: 1559-1564.
Spierings NMK, Natkunarajah J, Bansal A, Ostlere L. Should we be prescribing isotretinoin to patients with peanut allergies? Clin Exp Dermatol. 2015; 40(7): 824-825.
Pierret L, Grosber M, Gutermuth J. Is isotretinoin treatment safe in patients with known peanut allergy? J Eur Acad Dermatol Venereol. 2016; 30(1): 140-141.
Hulstaert E, Van Autryve E, Temmerman L. Is isotretinoin treatment safe in patients with known peanut allergy? Reply. J Eur Acad Dermatol Venereol. 2016; 30: 376.
Alvarez-Arango S, Hou A, Lowes MA, Jerschow E. Isotretinoin treatment in a patient with known peanut allergy and positive IgE test results for soybean. Ann Allergy, Asthma Immunol. 2016; 117(5): 558-559.
Alden K, Chowdhury MMU, Williams PE, Kalavala M. Protocol for investigation of possible soya allergy in patients being considered for treatment with isotretinoin or alitretinoin. Clin Exp Dermatol. 2016; 41(3): 326-327.
Peck GL, Olsen TG, Yoder FW, et al., Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med. 1979; 300: 329-333.
Jones H, Blanc D, Cunliffe WJ. 13-cis retinoic acid and acne. Lancet 1980; 2(8203): 1048-1049.
Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid: evaluation of sebum production and the clinical response in a multiple-dose trial. J Am Acad Dermatol. 1980; 3(6): 602-611.
Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris-10 years later: a safe and successful treatment. Br J Dermatol. 1993; 129(3): 292-296.
Lehucher-Ceyrac D, De La Salmonière P, Chastang C, Morel P. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999; 198(3): 278-283.
Borghi A, Mantovani L, Minghetti S, Giari S, Virgili A, Bettoli V. Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol. 2011; 25(9): 1094-1098.
Quéreux G, Volteau C, N'Guyen JM, Dréno B. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology 2006; 212(2): 168-176.
Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984; 10(3): 490-496.
Jones DH, Cunliffe WJ. Remission rates in acne patients treated with various doses of 13-cis-retinoic acid (isotretinoin). Br J Dermatol. 1984; 111(1): 123-125.
Jones DH, King K, Miller AJ, Cunliffe WJ. A dose-response study of 13-cis-retinoic acid in acne vulgaris. Br J Dermatol. 1983; 108(3): 333-343.
Lee JW, Yoo KH, Park KY, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol. 2011; 164(6): 1369-1375.
Agarwal U, Besarwal R, Bhola K. Oral isotretinoin in different dose regimens for acne vulgaris: a randomized comparative trial. Indian J Dermatol Venereol Leprol. 2011; 77(6): 688-694.
Rasi A, Behrangi E, Rohaninasab M, Nahad ZM. Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne. Adv Biomed Res. 2014; 3(1): 103.
Yap FB. Safety and efficacy of fixed-dose 10 mg daily isotretinoin treatment for acne vulgaris in Malaysia. J Cosmet Dermatol. 2017; 16(3): 348-352.
Rademaker M, Wishart JM, Birchall NM. Isotretinoin 5 mg daily for low-grade adult acne vulgaris - A placebo-controlled, randomized double-blind study. J Eur Acad Dermatol Venereol. 2014; 28(6): 747-754.
Rademaker M, Wishart J, Birchall N. Long term remission of persistent adult acne following very low-dose (5 mg/day) isotretinoin. Australas J Dermatol. 2017; 58(1): 69.
Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol. 1992; 27(6): S2-S7.
Leyden JJ, Del Rosso JQ, Baum EW. The use of isotretinoin in the treatment of acne vulgaris. J Clin Aesthet Dermatol. 2014; 7(2 Suppl): S3-21.
Ahmad HM. Analysis of clinical efficacy, side effects, and laboratory changes among patients with acne vulgaris receiving single versus twice daily dose of oral isotretinoin. Dermatol Ther. 2015; 28(3): 151-157.
Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol. 2016; 30(8): 1261-1268.
Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009; 1(3): 162-169.
Clark SM, Goulden V, Cunliffe WJ. The management of acne patients who respond slowly to oral isotretinoin. Br J Dermatol. 1996; 135(Supplement 47): 20.
Rubenstein R, Roenigk HH, Stegman SJ, Hanke CW. Atypical keloids after dermabrasion of patients taking isotretinoin. J Am Acad Dermatol. 1986; 15(2): 280-285.
Janssen de Limpens AM. The local treatment of hypertrophic scars and keloids with topical retinoic acid. Br J Dermatol. 1980; 103(3): 319-323.
Hunt TK, Ehrlich HP, Garcia JA, Dunphy JE. Effect of vitamin A on reversing the inhibitory effect of cortisone on healing of open wounds in animals and man. Ann Surg. 1969; 170(4): 633-641.
Larson DL, Flugstad NA, O'Connor E, Kluesner KA, Plaza JA. Does systemic isotretinoin inhibit healing in a porcine wound model? Aesthetic Surg J. 2012; 32(8): 989-998.
Dzubow LM, Miller WH. The effect of 13-cis-retinoic acid on wound healing in dogs. J Dermatological Surg Oncol. 1987; 13(3): 265-268
Moy RL, Moy LS, Bennett RG, Zitelli JA, Uitto J. Systemic isotretinoin: effects on dermal wound healing in a rabbit ear model in vivo. J Dermatological Surg Oncol. 1990;16: 1142-1146.
Arboleda B, Cruz NI. The effect of systemic isotretinoin on wound contraction in guinea pigs. Plast Reconstr Surg. 1989; 83(1): 118-121.
Moradi A, Aghaei S, Safaee-Ardekani G, Moradi M. Co-administration of NLite and Er: Yag Laser with Isotretinoin. Lasers Surg Med. 2009; 41(S21): 34-35.
Guadanhim LRS, Gonçalves RG, Bagatin E. Observational retrospective study evaluating the effects of oral isotretinoin in keloids and hypertrophic scars. Int J Dermatol. 2016; 55(11): 1255-1258.
Hann S-K, Cho M-Y, Jin S-H, Lee G-S. Concomitant use of infrared fractional laser with low dose isotretinoin. Lasers Surg Med. 2010; 42(S2): 22.
Spring LK, Krakowski AC, Alam M, et al. Isotretinoin and timing of procedural interventions: a systematic review with consensus recommendations. JAMA Dermatology. 2017; 153(8): 802-809.
Waldman A, Bolotin D, Arndt KA, et al. ASDS guidelines task force: consensus recommendations regarding the safety of lasers, dermabrasion, chemical peels, energy devices, and skin surgery during and after isotretinoin use. Dermatologic Surg. 2017; 43(10): 1249-1262.
Mysore V, Mahadevappa OH, Barua S, et al., Standard guidelines of care: performing procedures in patients on or recently administered with isotretinoin. J Cutan Aesthet Surg. 2017; 10: 186-194.
Bagatin E, Dos Santos Guadanhim LR, Yarak S, Kamamoto CSL, De Almeida FA. Dermabrasion for acne scars during treatment with oral isotretinoin. Dermatologic Surg. 2010; 36(4): 483-489.
Picosse F, Bagatin E, Guadanhim L, Cabral N, Yarak S. Early chemabrasion for acne scars after treatment with oral isotretinoin. J Am Acad Dermatol. 2012;66(4):AB207.
Xia J, Hu G, Hu D, Geng S, Zeng W. Concomitant Use of 1,550-nm nonablative fractional laser with low-dose isotretinoin for the treatment of acne vulgaris in Asian patients: a randomized split-face controlled study. Dermatol Surg. 2018; 44(9): 1201-1208.
Absorica Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021951s000lbl.pdf. Accessed April 20, 2020.
Caruana DM, Wylie G. “Washout” period for oral tetracycline antibiotics prior to systemic isotretinoin. Br J Dermatol. 2016; 174(4): 929-930.
Soria C, Allegue F, Galiana J, Ledo A. Decreased isotretinoin efficacy during acute alcohol intake. Dermatologica. 1991; 182: 203-205.
Fex G, Larsson K, Andersson A, Berggren-Soderlund M. Low serum concentration of all-trans and 13-cis retinoic acids in patients treated with phenytoin, carbamazepine and valproate Possible relation to teratogenicity. Arch Toxicol. 1995; 69(8): 572-574.
Marsden JR. Effect of isotretinoin on carbamazepine pharmacokinetics. Br J Dermatol. 1988; 119: 403-404.
Mandekou-Lefaki I, Delli F, Teknetzis A, Euthimiadou R, Karakatsanis G. Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharmacol Res. 2003; 23(2-3): 41-46.
Dhaked D, Meena R, Maheshwari A, Agarwal U, Purohit S. A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris. Indian Dermatol Online J. 2016; 7(5): 378.
Hermes B, Praetel C, Henz BM. Medium dose isotretinoin for the treatment of acne. J Eur Acad Dermatol Venereol. 1998; 11(2): 117-121.
Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol. 2006; 54(4): 644-646.
Sardana K, Garg VK, Sehgal VN, Mahajan S, Bhushan P. Efficacy of fixed low-dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris. J Eur Acad Dermatol Venereol. 2009; 23(5): 556-560.
Dipankar D, Kanwar AJ. Combination of low-dose isotretinoin and pulsed oral azithromycin in the management of moderate to severe acne: a preliminary open-label, prospective, non-comparative, single-centre study. Clin Drug Investig. 2011; 31(8): 599-604.
Rao PK, Bhat RM, Nandakishore B, Dandakeri S, Martis J, Kamath GH. Safety and efficacy of low-dose isotretinoin in the treatment of moderate to severe acne vulgaris. Indian J Dermatol. 2014; 59(3): 316.
Ballanger F, Baudry P, N'Guyen JM, Khammari A, Dréno B. Heredity: a prognostic factor for acne. Dermatology 2006; 212(2): 145-149.
Stainforth JM, Layton AM, Taylor JP, Cunliffe WJ. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol. 1993; 129(3): 297-301.
Goulden V, Clark SM, Mcgeown C, Cunliffe WJ. Treatment of acne with intermittent isotretinoin. Br J Dermatol. 1997; 137(1): 106-108.
Cakir GA, Erdogan FG, Gurler A. Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse. Int J Dermatol. 2013; 52(3): 371-376.